FSD1 Antibody, Biotin conjugated

Code CSB-PA861136LD01HU
Size US$166
Order now
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name
Rabbit anti-Homo sapiens (Human) FSD1 Polyclonal antibody
Uniprot No.
Target Names
FSD1
Alternative Names
Fibronectin type 3 and SPRY (spla; ryanodine) domain containing (with coiled-coil motif) 1 antibody; Fibronectin type 3 and SPRY domain containing 1 antibody; Fibronectin type III and SPRY domain containing 1 antibody; Fibronectin type III and SPRY domain-containing protein 1 antibody; Fibronectin type III and SPRY domains containing protein 1 antibody; FSD1 antibody; FSD1_HUMAN antibody; GLFND antibody; MGC3213 antibody; MGC58341 antibody; Microtubule-associated protein GLFND antibody; MID1-related protein 1 antibody; midline 1-related protein 1 antibody; MIR1 antibody; VLP27 antibody
Raised in
Rabbit
Species Reactivity
Human
Immunogen
Recombinant Human Fibronectin type III and SPRY domain-containing protein 1 protein (251-370AA)
Immunogen Species
Homo sapiens (Human)
Conjugate
Biotin
Clonality
Polyclonal
Isotype
IgG
Purification Method
>95%, Protein G purified
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Form
Liquid
Tested Applications
ELISA
Protocols
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Function
May be involved in microtubule organization and stabilization.
Gene References into Functions
  1. Overexpression of miR-1 mimics significantly decreased tumor glycolysis, including lactate production and glucose uptake, and cell proliferation, and these effects were reversed by ectopic expression of Smad3. PMID: 28471448
  2. These regulatory mechanisms of miR-1 expression could help us to understand the functions of altered miR-1 expression. PMID: 27923712
  3. Taken together, our findings established a tumor suppressive role for miR-1 in the progression of ccRCC by targeting CDK4, CDK6, Caprin1 and Slug and suggested miR-1 can be served as a novel potential therapeutic target for ccRCC. PMID: 26036633
  4. Data report the identification of MIR1, a protein with microtubule-binding activity which is located at the centrosome and is related to MID1/midin. [MIR1] PMID: 12154070
Subcellular Location
Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Nucleus. Cytoplasm. Cleavage furrow. Note=Cell-cycle-dependent association with the centrosome. Colocalizes with a subpopulation of microtubules. Does not associates with microtubules during mitosis but reassociates with microtubules during cytokinesis. Localizes to the central portions of a small subset of microtubules in interphase cells and a subpopulation of microtubules in the cleavage furrow, not present in the mitotic spindle.
Tissue Specificity
Highly expressed in brain tissues, including cerebellum, cerebral cortex, medulla, occipital pole, frontal lobe, temporal lobe and putamen. Lower expression in spinal chord.
Database Links

HGNC: 13745

OMIM: 609828

KEGG: hsa:79187

STRING: 9606.ENSP00000221856

UniGene: Hs.28144

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2024 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*